Barely Significant
← all excerpts

CAR-T Cell Therapy in Large B Cell Lymphoma.

Mediterr J Hematol Infect Dis · 2023 · PMC10631715 · PMID 38028399

1
hedged sentence
closest p
boldest claim

The sentences

showed a trendno p-value reported
47 Furthermore, patients in the CAR-T group showed a trend to lower non-relapse mortality compared to those in the auto-HSCT group. 47 According to these observations, the authors suggest that in older patients with refractory/relapsed DLBCL patients achieving a partial response to salvage chemotherapy, CAR-T treatment resulted in outcomes comparable to auto-HSCT. 47 Allogeneic HSCT and CAR-T Therapy after Auto-HSCT Failure in DLBCL A retrospective noncomparative registry study analyzed outcomes in 584 patients with DLBCL undergoing a reduced intensity allo-HSCT or CAR-T therapy with Axi-Cel after a prior auto-HSCT failure.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.